Charles Triano | Senior Vice President of Investor Relations. |
Ian Read | Chairman and Chief Executive Officer. |
Frank D'Amelio | Chief Financial Officer. |
Albert Bourla | Chief Operating Officer. |
Mikael Dolsten | President of Worldwide Research and Development. |
John Young | Group President of Pfizer Innovative Health. |
Douglas Lankler | General Counsel |
Alex Arfaei | BMO Capital Markets |
Vamil Divan | Credit Suisse |
David Risinger | Morgan Stanley |
Geoff Meacham | Barclays |
Jeff Holford | Jefferies |
Jason Gerberry | Bank of America |
John Boris | SunTrust |
Greg Gilbert | Deutsche Bank |
Jami Rubin | Goldman Sachs |
Andrew Baum | Citi |
Tony Butler | Guggenheim Partners |
Chris Schott | JPMorgan |
Tim Anderson | Bernstein |
Marc Goodman | UBS |
Steve Scala | Cowen |
Umer Raffat | Evercore |
Seamus Fernandez | Leerink |
Good day, everyone, and welcome to Pfizer's Fourth Quarter 2017 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Mr. Chuck Triano, Senior Vice President of Investor Relations. Please go ahead, sir.